Article

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumors

2026-02-19

Abstract excerpt

Rare cancers are individually uncommon but collectively represent a substantial share of cancer burden, with limited systemic treatment options for many entities. Molecular profiling identifies targetable alterations, but actionable findings are limited and responses can vary despite a matched target. This motivates complementary approaches that directly assess tumor drug response. Here, we establish a biopsy-comp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ba4c41db-300e-523a-b101-6fc2b4eaf974
DOI: 10.64898/2026.02.18.705724

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsDOI 10.64898/2026.02.18.705724Read

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read

Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy ResponseSemantic proximity Read

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.Semantic proximity Read

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.Semantic proximity Read

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read

Special report: multiple molecular testing of cancers to identify targeted therapies.Semantic proximity Read

Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer TherapySemantic proximity Read

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read

Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistanceSemantic proximity Read

Functional Drug Screening in the Era of Precision MedicineSemantic proximity Read